Last reviewed · How we verify

NCT02844335

Combination of Cryosurgery and NK Immunotherapy for Advanced Breast Cancer

Completed Phase 1, PHASE2 Last updated 12 September 2019
What this trial tests

Phase 1, PHASE2 trial testing Cryosurgery in Breast Cancer Recurrent in 60 participants. Completed in 1 July 2019.

Timeline
1 July 2016
Primary endpoint
1 July 2017
1 July 2019

Quick facts

Lead sponsorFuda Cancer Hospital, Guangzhou
PhasePhase 1, PHASE2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment60
Start date1 July 2016
Primary completion1 July 2017
Estimated completion1 July 2019
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Fuda Cancer Hospital, Guangzhou

Who can join

Adults 30 to 70, any sex, with Breast Cancer Recurrent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to advanced breast cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. NK cell-based cancer immunotherapy: from basic biology to clinical development.
    Liu S, Galat V, Galat Y, Lee YKA, et al · · 2021 · cited 504× · PMID 33407739 · DOI 10.1186/s13045-020-01014-w
  2. Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors.
    Melaiu O, Lucarini V, Cifaldi L, Fruci D. · · 2019 · cited 324× · PMID 32038612 · DOI 10.3389/fimmu.2019.03038
  3. Immunotherapeutic interventions of Triple Negative Breast Cancer.
    Li Z, Qiu Y, Lu W, Jiang Y, et al · · 2018 · cited 99× · PMID 29848327 · DOI 10.1186/s12967-018-1514-7
  4. Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors.
    Yakkala C, Chiang CL, Kandalaft L, Denys A, et al · · 2019 · cited 67× · PMID 31608067 · DOI 10.3389/fimmu.2019.02283
  5. Trial Watch: Adoptively transferred cells for anticancer immunotherapy.
    Fournier C, Martin F, Zitvogel L, Kroemer G, et al · · 2017 · cited 55× · PMID 29147628 · DOI 10.1080/2162402x.2017.1363139
  6. Photodynamic Therapy and Hyperthermia in Combination Treatment-Neglected Forces in the Fight against Cancer.
    Bienia A, Wiecheć-Cudak O, Murzyn AA, Krzykawska-Serda M. · · 2021 · cited 36× · PMID 34452108 · DOI 10.3390/pharmaceutics13081147
  7. The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy.
    Abakushina EV, Popova LI, Zamyatnin AA, Werner J, et al · · 2021 · cited 29× · PMID 34835294 · DOI 10.3390/vaccines9111363
  8. Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer.
    Sabry M, Lowdell MW. · · 2020 · cited 21× · PMID 32416056 · DOI 10.1002/sctm.19-0423

Verify or expand the search:

Other trials of Cryosurgery

Trials testing the same drug.

Other recruiting trials for Breast Cancer Recurrent

Currently open trials in the same condition.

Other Fuda Cancer Hospital, Guangzhou trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02844335.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing